Ultime notizie per Anywhere Real Estate (NYSE:HOUS) Azioni

Anywhere Real Estate

Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 12.01% on an annualized basis producing an average annual return of 26.44%. Currently, East West Bancorp has a market capitalization of $14.90 billion. 
Buying $100 In EWBC: If an investor had bought $100 of EWBC stock 5 years ago, it would be worth $313.72 today based on a price of $108.14 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752186613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

EWBC

$100 Invested In East West Bancorp 5 Years Ago Would Be Worth This Much Today

Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) has outperformed the market over the past 5 years by 42.65% on an annualized basis producing an average annual return of 57.09%. Currently, Targa Resources has a market capitalization of $37.04 billion. 
Buying $1000 In TRGP: If an investor had bought $1000 of TRGP stock 5 years ago, it would be worth $9,984.80 today based on a price of $170.74 for TRGP at the time of writing.
<h3>Targa Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752185712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TRGP

Here's How Much You Would Have Made Owning Targa Resources Stock In The Last 5 Years

UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) with a Buy and lowers the price target from $30 to $26.

Price Target

Analyst Ratings

NRIX

UBS Maintains Buy on Nurix Therapeutics, Lowers Price Target to $26

UBS analyst Robin Farley maintains Choice Hotels Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>) with a Neutral and lowers the price target from $160 to $149.

UBS Maintains Neutral on Choice Hotels Intl, Lowers Price Target to $149

UBS analyst Kenneth Fong maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $58 to $50.

UBS Maintains Buy on JD.com, Lowers Price Target to $50

Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has high hopes for its "Superman" reboot film, set for theaters this weekend. The film has been<a href="https://www.benzinga.com/general/entertainment/22/12/30116813/its-a-bird-its-a-plane-its-a-superhero-movie-franchise-rebrand-that-could-help-this-stock" target="_blank" rel="noopener"> years in the making</a> and is a potential relaunch of the DC Comics movie universe, but one former Superman actor is crying foul over the plot.
What Happened: Director James Gunn was announced <a href="https://www.benzinga.com/general/entertainment/23/02/30678077/its-a-bird-its-a-plane-its-dc-comics-new-movies-tv-shows-announced">as the man behind </a>the "Superman" reboot years ago and the man tasked with helping turn DC Comics&#8217; film and TV strategy around.
Gunn's new superhero film is being called "woke" by actor Dean Cain, who famously played Superman in the TV show "Lois &amp; Clark" from 1993 to 1997.
"How woke is Hollywood going to make this character?" Cain told <a href="https://www.tmz.com/2025/07/09/superman-dean-cain-immigrant-controversy/">TMZ</a>. "How much is Disney going to change their Snow White? Why are they going to change their characters (to) exist for the times?"
Cain's comments, reported by <a href="https://variety.com/2025/film/news/dean-cain-superman-woke-maga-backlash-immigrant-1236451732/">Variety</a>, come after Gunn shared that Superman is an "immigrant that came from other places and populated the country" in the film, adding that the film represents "the story of America."
"For Superman, it was ‘truth, justice, and the American way.' Well, they dropped that…They came up with ‘truth, justice, and a better tomorrow.' Changing beloved characters I don't think is a great idea. If you want to create a new character go ahead and do that," Cain also said.
Cain went on to criticize America's immigration policies.
"There have to be limits, because we can't have everybody in the United States. We can't have everybody, society will fail. So there have to be limits."
Cain's not the only one speaking out about the film's plot line, in which Superman is portrayed as an immigrant.
Fox News recently referred to the film as "SuperWoke."
Fox News contributor Kellyanne Conway criticized the film&#8217;s plot line.
"We don't go to the movie theater to be lectured to and to have somebody throw their ideology onto us," Conway said.
Gunn has brushed off the criticism ahead of the film's July 11 release, telling Variety he doesn't have "anything to say to anybody" spreading hate about his film.
"I think this is a movie about kindness and I think that's something everyone can relate to," Gunn said.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">Top Anticipated 2025 Movies For Big Screen Success And Stocks Investors Should Watch</a>
Why It's Important: The potential boycott of the film by Republicans and public criticism from a former Superman actor could end up hurting the film's box office.
"I think it was a mistake by James Gunn to say it's an immigrant thing, and I think it's going to hurt the numbers on the movie," Cain said.
The film is expected to gross $120 million to $130 million domestically in its opening weekend, according to <a href="https://variety.com/2025/film/box-office/superman-box-office-opening-weekend-projection-1236448799/">Variety</a>. The studio has been more conservative with estimates saying it expects $100 million to $110 million.
Early positive reactions from critics and fans could also take the film past $140 million domestically, according to the report. On Rotten Tomatoes, the film has an 82% rating from critics and a 96% rating from early viewers of the film.
The "Superman" film had a $225 million production budget and could also gross $100 million in international markets in its opening weekend.
The last standalone Superman film was "Man of Steel" in 2013. That film <a href="https://www.boxofficemojo.com/franchise/fr340233989/?ref_=bo_frs_table_6">grossed </a>$291.0 million domestically with an opening domestic weekend total of $116.6 million. The last film featuring Superman was Justice League, released in 2017, which grossed $229.0 million domestically and opened with $93.8 million.
The best recent Superman film performance is 2016's "Batman vs. Superman: Dawn of Justice." That film grossed $330.4 million domestically and opened to a $166.0 million domestic total.
WBD Price Action: Warner Bros. Discovery shares were up 1.4% to $11.65 on Thursday versus a 52-week trading range of $6.64 to $12.76. Warner Bros. stock is up 9.3% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45320845/warner-bros-stock-jumps-on-streaming-growth-the-last-of-us-minecraft-movie-could-mean-even-bigger-gains-in-q2">Warner Bros. Stock Jumps On Streaming Growth: &#8216;The Last Of Us,&#8217; &#8216;Minecraft Movie&#8217; Could Mean Even Bigger Gains In Q2</a></li>
</ul>
Photo: John B Hewitt / Shutterstock.com

Entertainment

Politics

Superman An Immigrant? Superhero Actor Says Warner Bros. Film Is Woke, Issues Box Office Warning

UBS analyst Douglas Harter maintains Two Harbors Inv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) with a Buy and lowers the price target from $13 to $12.

UBS Maintains Buy on Two Harbors Inv, Lowers Price Target to $12

UBS analyst Brock Vandervliet maintains AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) with a Neutral and raises the price target from $8.5 to $9.5.

AGNC

UBS Maintains Neutral on AGNC Investment, Raises Price Target to $9.5

UBS analyst Doug Harter maintains Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) with a Neutral and raises the price target from $10 to $10.5.

AOMR

UBS Maintains Neutral on Angel Oak Mortgage REIT, Raises Price Target to $10.5

UBS analyst Douglas Harter maintains ARMOUR Residential REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARR#NYSE">ARR</a>) with a Neutral and raises the price target from $14 to $16.

UBS Maintains Neutral on ARMOUR Residential REIT, Raises Price Target to $16

UBS analyst Douglas Harter maintains Chimera Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>) with a Buy and raises the price target from $15 to $16.

UBS Maintains Buy on Chimera Investment, Raises Price Target to $16

Ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.75, a high estimate of $65.00, and a low estimate of $64.00. This current average has decreased by 10.07% from the previous average price target of $72.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184856_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Ultragenyx Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Sami Corwin</td>
<td>William Blair</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Ultragenyx Pharmaceutical</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Ultragenyx Pharmaceutical's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.99% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -108.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -75.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.73%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio stands notably higher than the industry average, reaching 0.27. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RARE

Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views

Granite Point Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPMT#NYSE">GPMT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $2.69, with a high estimate of $3.25 and a low estimate of $2.25. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184847_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Granite Point Mortgage among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$2.75</td>
<td>$2.25</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$3.25</td>
<td>$2.50</td>
</tr>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$2.25</td>
<td>$2.50</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$2.50</td>
<td>$3.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Granite Point Mortgage. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Granite Point Mortgage compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Granite Point Mortgage's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Granite Point Mortgage's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GPMT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Granite Point Mortgage analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Granite Point Mortgage</h2>
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
<h3>Understanding the Numbers: Granite Point Mortgage's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Granite Point Mortgage's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -17.79%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Granite Point Mortgage's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -105.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Granite Point Mortgage's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.74%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Granite Point Mortgage's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.42.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GPMT

Expert Outlook: Granite Point Mortgage Through The Eyes Of 4 Analysts

Analysts' ratings for Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $181.67, along with a high estimate of $200.00 and a low estimate of $152.00. This upward trend is apparent, with the current average reflecting a 6.45% increase from the previous average price target of $170.67.
<img src="https://www.benzinga.com/files/images/story/2025/1752184839_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Ares Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$189.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$197.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ares Management. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ares Management compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ares Management's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ares Management's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Management analyst ratings.</a>
<h2>Delving into Ares Management's Background</h2>
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate &amp; infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, &amp; credit.
<h3>Ares Management: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Ares Management's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 53.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Ares Management's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.01%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Ares Management's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.86%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.08%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ares Management's debt-to-equity ratio surpasses industry norms, standing at 4.46. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Ares Management Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

5 analysts have expressed a variety of opinions on Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Starwood Property Trust, presenting an average target of $19.8, a high estimate of $22.00, and a low estimate of $19.00. Marking an increase of 0.51%, the current average surpasses the previous average price target of $19.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184831_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Starwood Property Trust by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$19.50</td>
<td>$19.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$19.50</td>
<td>$19.00</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Starwood Property Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Starwood Property Trust compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Starwood Property Trust's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Starwood Property Trust's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STWD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Starwood Property Trust analyst ratings.</a>
<h2>All You Need to Know About Starwood Property Trust</h2>
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing &amp; Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
<h3>Starwood Property Trust's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Starwood Property Trust's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -39.02% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Starwood Property Trust's net margin excels beyond industry benchmarks, reaching 60.02%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Starwood Property Trust's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.18%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.4, Starwood Property Trust adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STWD

Where Starwood Property Trust Stands With Analysts

Analysts' ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $78.71, a high estimate of $92.00, and a low estimate of $70.00. This upward trend is apparent, with the current average reflecting a 8.36% increase from the previous average price target of $72.64.
<img src="https://www.benzinga.com/files/images/story/2025/1752184824_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Joel Jackson</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Laurence Alexander</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Corteva's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corteva analyst ratings.</a>
<h2>Unveiling the Story Behind Corteva</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Corteva: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Corteva's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -1.67% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin excels beyond industry benchmarks, reaching 14.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.57%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

A Glimpse Into The Expert Outlook On Corteva Through 14 Analysts

In the current session, the stock is trading at $38.17, after a 1.14% increase. Over the past month, Zurn Elkay Water Solns Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) stock increased by 5.91%, and in the past year, by 25.93%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1752184818_0.png" alt="Past Year Chart" />

<h3>Comparing Zurn Elkay Water Solns P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 26.37 in the Building Products industry, Zurn Elkay Water Solns Inc. has a higher P/E ratio of 39.31. Shareholders might be inclined to think that Zurn Elkay Water Solns Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752184818_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Zurn Elkay Water Solns Inc's Price Over Earnings

FirstCash Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) has outperformed the market over the past 20 years by 4.76% on an annualized basis producing an average annual return of 13.24%. Currently, FirstCash Hldgs has a market capitalization of $5.89 billion. 
Buying $100 In FCFS: If an investor had bought $100 of FCFS stock 20 years ago, it would be worth $1,238.82 today based on a price of $132.74 for FCFS at the time of writing.
<h3>FirstCash Hldgs's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752184817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCFS

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

In the last three months, 6 analysts have published ratings on DTE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $143.67, a high estimate of $154.00, and a low estimate of $134.00. This current average has increased by 3.73% from the previous average price target of $138.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184816_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of DTE Energy among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Campanella</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Ryan Levine</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$151.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Arcaro</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$134.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Neil Kalton</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>James Thalacker</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$142.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DTE Energy. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of DTE Energy compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for DTE Energy's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into DTE Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DTE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DTE Energy analyst ratings.</a>
<h2>Get to Know DTE Energy Better</h2>
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.
<h3>A Deep Dive into DTE Energy's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: DTE Energy's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 37.04%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.
Net Margin: DTE Energy's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 10.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DTE Energy's ROE stands out, surpassing industry averages. With an impressive ROE of 3.76%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DTE Energy's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.9%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.97.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess DTE Energy: What You Need To Know

UBS analyst Doug Harter maintains Dynex Cap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DX#NYSE">DX</a>) with a Neutral and raises the price target from $11 to $12.5.

UBS Maintains Neutral on Dynex Cap, Raises Price Target to $12.5

Offerings

Press Releases

Real Estate

Anywhere Announces Proposed Offering of Senior Secured Second Lien Notes

Guaranteed Rate Affinity Appoints Linda Vo as Regional Manager in North Texas

Coldwell Banker Real Estate Unveils 2025 List of "30 Under 30" Honorees

Anywhere Announces Pricing of Senior Secured Second Lien Notes

Penny Stocks

Small Cap

Anywhere Appoints Barri Rafferty as Chief Communications Officer and Head of Public Affairs

Insurance

Title Resources Group Appoints Natasha Branch as Underwriting Counsel for North Carolina

Coldwell Banker Real Estate Report: Demand for Luxury Real Estate Holds Strong; More Affluent Home Buyers Paying in Cash Amid Rate Pressures

THE SOTHEBY'S INTERNATIONAL REALTY BRAND RELEASES 2025 MID-YEAR LUXURY OUTLOOK REPORT, FINDING LUXURY REAL ESTATE REMAINS A SAFE HAVEN AMID MARKET UNCERTAINTIES

Anywhere Appoints Tom Hudson as Head of Investor Relations

Title Resources Group Appoints Michael Campbell as Underwriting Counsel for Michigan

HOUS

OPEN

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

Anywhere Real Estate

Notizie

Ultime notizie per Anywhere Real Estate (NYSE:HOUS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO